Bryan Wahl - 09 Mar 2022 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
General Counsel
Signature
/s/ Leonard M. Greenstein, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
09 Mar 2022
Net transactions value
$0
Form type
4
Filing time
11 Mar 2022, 15:15:23 UTC
Next filing
01 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +65,312 $0.000000 65,312 09 Mar 2022 Common Stock 65,312 $19.59 Direct F1
transaction TARS Restricted Stock Units Award $0 +19,160 $0.000000 19,160 09 Mar 2022 Common Stock 19,160 Direct F2, F3
transaction TARS Restricted Stock Units Award $0 +34,171 $0.000000 34,171 09 Mar 2022 Common Stock 34,171 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.
F4 30% of the RSUs will vest on November 29, 2022 and 70% of the RSUs will vest on November 29, 2023 subject to the Reporting Person's continuous service.